Samsung Biologics signs vaccine partnership with CEPI
Samsung Biologics, the biotech arm of Korea's Samsung Group, said Wednesday it will collaborate with the Coalition for Epidemic Preparedness Innovations (CEPI) to jointly respond to future pandemic outbreaks. The company said it has signed a Vaccine Manufacturing Facility Network (VMFN) partnership with CEPI to ensure the rapid supply of vaccines in the event of a global pandemic. By joining CEPI's global VMFN, Samsung Biologics will provide CEPI with guaranteed access to up to 50 million vaccine doses, along with an additional one billion doses of drug substance ready for conversion into finished vaccine products, the company said in a press release. "By working with CEPI to advance vaccine development and ensure capacity for timely production when demand rises, we aim to broaden access to high-quality vaccines for patients around the world. We will continue to apply our technical and manufacturing expertise to strengthen global preparedness," said John Rim, president and chief executive officer (CEO) of Samsung Biologics. CEPI CEO Richard Hatchett said partnering with one of the world'Weiter zum vollständigen Artikel bei Korea Times
Ausgewählte Hebelprodukte auf Samsung
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Samsung
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Korea Times
